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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To quantify the incidence of any reported adverse event in patients taking cephalosporins compared with placebo for any indication.
B A C K G R O U N D
Description of the condition
Use of cephalosporin antibiotics (known as cephalosporins) varies,
with usage as low as 0.2% in Denmark and as high as 23.5% in
Malta (ECDC 2014). Variations in cephalosporin use may be due
to concerns about the development of antibiotic resistance. Indica-
tions include: respiratory tract infections (acute otitis media, bac-
terial sinusitis, severe pneumonia), bacterial meningitis, urinary
tract infections, septicaemia, surgical prophylaxis, skin and soft tis-
sue infections, and gonorrhoea (Australian Medicines Handbook
2015).
Description of the intervention
Cephalosporins are a subclass of the β-lactams. The list of Inter-
national Nonproprietary Names, compiled by the World Health
Organization (WHO), contains 80 cephalosporins (WHO2016),
all of which share a common β-lactam ring and have medium to
broad spectrum activity against both Gram-positive and Gram-
negative bacterial species (Rang 2015), including Pseudomonas
aeruginosa (P aeruginosa), Streptococcus pneumoniae (S pneumo-
niae), Staphylococcus aureus (S aureus), Haemophilus influenzae (H
influenzae), Klebsiella pneumoniae (K pneumoniae), and Escherichia
coli (E coli) (Therapeutic Guidelines 2014). Cephalosporins are
often referred to as first, second, or third generation, based on the
order in which they were developed.
An adverse event is an adverse outcome that occurs while a patient
is taking a drug, but the event is not (or not necessarily) attributable
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to the drug taken (Edwards 2000).
It has been recommended that the recording of adverse events
in clinical trials should distinguish suspected adverse effects from
suspected adverse reactions (Aronson 2013), defined as follows.
1. Adverse effects are unwanted outcomes of which the patient
is not aware; they are usually detected by laboratory tests (e.g.
biochemical, haematological, immunological, radiological,
pathological tests) or by clinical investigations (e.g.
gastrointestinal endoscopy, cardiac catheterisation).
2. Adverse reactions are unwanted outcomes that the patient
experiences and are detected by their clinical manifestations
(symptoms and/or signs).
3. Serious adverse events are often reported separately. These
are adverse events that occur at any dose, and result in death or
life-threatening events; requirement for hospitalisation or
prolongation of existing hospitalisation; persistent or significant
disability; or congenital anomalies; or are events that are
considered medically important (ICH 2003).
Recent guidance suggests that clinical trial authors should report
all adverse events that occur in more than 5% of any group (Zarin
2016). The events can be classified by the 27 SystemOrganClasses
(e.g. blood and lymphatic systemdisorders) definedby theMedical
Dictionary for Regulatory Activities (MedDRA) or the 335 High
Level Group Terms of this classification (MedDRA 2016).
How the intervention might work
Antibiotics can cause unwanted events in different ways.
1. Hypersensitivity reactions, in which the host generates an
immune response to the drug, perhaps manifesting as a rash (Ibia
2000), and which can occur even at doses that are below the
usual therapeutic range.
2. Adverse reactions that occur at doses in the usual
therapeutic range (called collateral reactions). Some of these can
occur through direct adverse effects (e.g. nausea and vomiting
due to altered gastric emptying; Kuo 1998); and others through
destruction of commensals (disturbing the equilibrium of the
microbiome, which might cause diarrhoea from an overgrowth
of Clostridium difficile (C difficile); or thrush from an
overgrowth of Candida).
3. Adverse reactions that occur at high doses (toxic reactions).
4. Induction of antibiotic resistance in micro-organisms in the
microbiome, which may affect individuals in the general
population. Since resistance can be transmitted between
organisms, the risk of harm from resistant micro-organisms
extends beyond the individual. It is not possible to determine the
extent of this harm from individually randomised trials, and this
is therefore beyond the scope of the current review.
Why it is important to do this review
Adverse events in those taking antibiotics are usually measured by
observational mechanisms: anecdotal reporting; voluntary organ-
ised reporting; intensive event monitoring; and observational re-
search studies (Edwards 2000). These approaches are susceptible
to reporting biases (Edwards 2000); and misclassification of the
cause of events which could be due to the antibiotic or the under-
lying disease for which it was prescribed. Randomised controlled
trials (RCTs) of antibiotics, the gold standard for determining ef-
ficacy of interventions, are often underpowered to detect differ-
ences in adverse events (Chen 2014). Several systematic reviews of
RCTs in the Cochrane Library have reported on adverse events in
those taking cephalosporins (Kilburn 2010; Paul 2010), but noted
that there were insufficient data on adverse events to make clear
conclusions (Kilburn 2010). Oneway of overcoming this problem
is to carry out a ‘multi-indication’ review i.e. a review of the effects
of an intervention in all participants using the intervention for
any reason (indication). This type of review is particularly useful
for detecting rare events like adverse events, where the mechanism
of action is unrelated to the indication (Chen 2014). This review
is the third in a series of multi-indication reviews investigating
adverse events in those taking antibiotics (Gillies 2015; Plejdrup
Hansen 2015).
O B J E C T I V E S
To quantify the incidence of any reported adverse event in patients
taking cephalosporins compared with placebo for any indication.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs). We will ex-
clude pharmacodynamic studies of events that are not considered
to be adverse events (e.g. studies that test gastrointestinal motil-
ity after ingestion of cephalosporins); pharmacokinetic studies of
events that are not considered to be adverse events (e.g. testing
interactions with other drugs); and studies with less than 20 par-
ticipants randomised to each arm.
Types of participants
We will include individuals of all ages taking cephalosporins for
any indication.
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Types of interventions
We will include trials comparing cephalosporins delivered by any
route (per oral, intravenous, intramuscular, or per rectal) with
placebo. Use of concomitant medications is permitted.
Types of outcome measures
Primary outcomes
1. A composite outcome of all adverse events of any kind (that
occur in 5% or more of any group; Zarin 2016).
2. Serious adverse events.
3. Subsequent carriage of resistant bacteria (measured at any
time point post-treatment).
Secondary outcomes
1. Adverse events (that occur in 5% or more of any group;
Zarin 2016) organised by System Organ Classes listed in the
MedDRA, and where there is enough information, High Level
Terms of this classification (MedDRA 2016).
Reporting one or more of the outcomes listed here in the trial is
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We will search the following databases from inception to present.
1. CENTRAL (Cochrane Central Register of Controlled
Trials).
2. PubMed (MEDLINE).
3. Embase.
We will use the search strategy described in Appendix 1 to
search CENTRAL (Cochrane Central Register of Controlled Tri-
als), which contains the Cochrane Acute Respiratory Infections
(ARIs) Group’s Specialised Register and PubMed (MEDLINE).
We will use the Cochrane Highly Sensitive Search Strategy for
randomised trials: sensitivity and precision-maximising version
(2008 revision) (Lefebvre 2011). We will adapt the search strat-
egy to search Embase. We will also conduct a search of the
WHO International Clinical Trials Registry Platform (WHO
ICTRP) (apps.who.int/trialsearch), which contains ClinicalTri-
als.gov (www.ClinicalTrials.gov). We will not impose language,
publication date, or publication status restrictions.
To develop the search strategy, one of the review authors (JA)
provided a list of common cephalosporins from the WHO list of
International Nonproprietary Names (WHO 2016; see Appendix
2). After an initial review of the search results using this list in
the search strategy, we decided to supplement it with additional
terms. We did this using a four-step process.
1. We identified all cephalosporins listed in the Mesh database
as well as any relevant entry terms from their MeSH entries and
combined this list with the original list provided by the review
author; this gave a list of 186 terms.
2. We removed trade names from the list; this left 127 terms.
3. Where a term contained an ’f ’, for example, cefazolin, we
added a new term using ’ph’ instead, for example, cephazolin.
This created a list of 206 terms.
4. One of the review authors (JA) undertook a final check of
the terms to remove any remaining trade names. This left 158
terms which were incorporated into the search strategy.
Searching other resources
We will conduct a forward and backward citation analysis of all
included studies to look for additional references. We will contact
the authors of trials of cephalosporins versus placebo and ask for
adverse events data if they are not published.
Data collection and analysis
Selection of studies
Pairs of review authors (AMcC,AS,CM)will independently screen
titles and abstracts resulting from the searches. We will retrieve all
potentially eligible full-text articles for full-text screening. Pairs of
review authors (AMcC, AS, CM) will independently screen the
full-text and identify studies for inclusion, and identify and record
reasons for exclusion of the ineligible studies. We will resolve any
disagreement through discussion or, if required, we will consult a
third review author (CDM or EB). We will identify and exclude
duplicates and collate multiple reports of the same study so that
each study rather than each report is the unit of interest in the
review. We will record the selection process in sufficient detail to
complete a PRISMA flow diagram (Moher 2009), and ’Charac-
teristics of excluded studies’ table.
Data extraction and management
Pairs of review authors (AMcC, AS, CM) will independently ex-
tract the following data using a standardised data extraction form
(piloted on at least one study in the review), which will include
the following information.
1. Methods: study design, year of publication, clinical trial
registration, study setting, study population, and information to
assess risk of bias (see below).
2. Participants: N, mean age or age range, gender.
3. Interventions: intervention (indication, route of
administration, dose, and duration), comparison, and
concomitant medications.
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4. Outcomes: any adverse events reported, times of
measurements, and the methods used to elicit adverse events
data.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
We will note in the ’Characteristics of included studies’ table if
outcome data are not reported in a usable way. We will resolve
disagreements by consensus or by involving a third review author
(CDM or EB).
Assessment of risk of bias in included studies
Pairs of review authors (AMcC, AS, CM)will independently assess
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another review author (CDM or EB). We will assess the risk of
bias according to:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting; and
7. other bias.
We will grade each potential source of bias as ’high’, ’low’ or ’un-
clear’ and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the risk of bias judgements across different studies for
each of the domains listed using a ’Risk of bias’ summary figure.
We will consider blinding separately for different key outcomes,
where necessary. Where information on risk of bias relates to un-
published data or correspondence with a trialist, we will note this
in the ’Risk of bias’ table. When considering treatment effects, we
will take into account the risk of bias for the studies that contribute
to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
Where possible, we will enter the outcome data for each study into
the data tables in Review Manager 5 to calculate the treatment
effects (RevMan 2014). We plan to express all outcomes as Peto
odds ratios (ORs), with accompanying 95% confidence intervals
(CIs), as we assume that the included trials will report few adverse
events. However, we will only use this approach on condition of
meeting the relevant criteria for using Peto’smethod as stated in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011):
1. when interventions effects are small;
2. when events are not particularly common; and
3. the studies have similar numbers in the experimental and
control group.
We will express ORs as absolute risk differences (RDs), based on
assumed/average rates of adverse events in the control groups, and
convert to the number needed to treat to harm (NNTH) to inter-
pret the results from the meta-analysis. We will undertake meta-
analyses only where this is meaningful, i.e. if the treatments, par-
ticipants, and the underlying clinical question are similar enough
for pooling to make sense.
Unit of analysis issues
We will use the patient as the unit of analysis, where reported. If
antibiotic resistance is reported by proportion of isolated bacteria
(rather than by patient), thenwewill use this as the unit of analysis.
Dealing with missing data
We will contact trial authors to obtain additional information
if reporting of data is incomplete or if the data are missing. If
no information about missing data is available, and the data are
thought to introduce bias, we will explore the impact of including
such studies in the overall results using a sensitivity analysis.
Assessment of heterogeneity
We will use: (1) visual inspection of forest plots; (2) statistical test
of heterogeneity (Chi2 test); and, (3) measure of inconsistency (I²
statistic) tomeasure heterogeneity among the trials in each analysis.
If we identify substantial heterogeneity (> 50%), we will report
it and explore possible causes by prespecified subgroup analysis
(Higgins 2011).
Assessment of reporting biases
We will minimise reporting bias by conducting a comprehensive
search for relevant study protocols and unpublished trials. Out-
come reporting bias may be particularly important for adverse
events, and we will clarify whether all outcomes listed in the study
protocols are published and whether the outcomes were prede-
fined (Higgins 2011). If we are able to pool more than 10 trials,
we will create and examine a funnel plot to explore possible small
study and publication biases.
Data synthesis
We will pool data from studies we judge to be clinically homoge-
neous using Review Manager 5 software (RevMan 2014). If more
than one study provides usable data in any single comparison, we
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will perform a meta-analysis. We will summarise every reported
adverse event with a meta-analysis of the OR using fixed-effects
models presented with 95% CIs. Where it is not possible to com-
bine data statistically, we will report outcomes narratively.
GRADE and ’Summary of findings’ table
We will create a ’Summary of findings’ table which will include
the following outcomes: a composite outcome of all adverse events
of any kind (that occur in 5% or more of any group; Zarin 2016);
serious adverse events; subsequent carriage of resistant bacteria
(measured at any time point post-treatment); and, adverse events
(that occur in 5% or more of any group; Zarin 2016) organised
by System Organ Classes listed in the MedDRA, and where there
is enough information, High Level Terms of this classification
(MedDRA 2016). We will use the five GRADE considerations
(study limitations, consistency of effect, imprecision, indirectness,
and publication bias) to assess the quality of a body of evidence as
it relates to the studies which contribute data to the meta-analyses
for the prespecified outcomes (Atkins 2004). We will use methods
and recommendations described in Section 8.5 and Chapter 12
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), using GRADEpro software (GRADEpro GDT
2014).We will justify all decisions to down- or upgrade the quality
of studies using footnotes, and we will make comments to aid the
reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses.
1. Age groups (children or adults).
2. First, second, or third generation of cephalosporin.
3. Route of administration (per oral, intravenous,
intramuscular, per rectal).
4. Antibiotic dosage (dose and frequency of administration).
5. Duration of therapy.
Wewill use theChi² test to test for subgroup interactions inReview
Manager 5 (RevMan 2014).
Sensitivity analysis
We will perform a sensitivity analysis by excluding those studies
found to have a high risk of bias. If a study has more than 20% of
randomised participants with missing data for the outcome (lost
to follow-up/reporting of adverse events), we will exclude it from
the primary analysis, but include it in a sensitivity analysis.
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A P P E N D I C E S
Appendix 1. Pubmed (MEDLINE) search strategy
(“Cephalosporins”[Mesh] OR Cephalosporins[tiab] OR Cephalosporin[tiab] OR Cephalosporanic[tiab] cefacetrile[tiab] OR ce-
fadroxil[tiab] OR cefaclor[tiab] OR cefadroxil[tiab] OR cefalexin[tiab] OR cefaloglycin[tiab] OR cefalonium[tiab] OR cefaloram[tiab]
OR cefaloridine[tiab] OR cefalotin[tiab] OR cefamandole[tiab] OR cefaparole[tiab] OR cefapirin[tiab] OR cefatriaxone[tiab] OR cefa-
trizine[tiab] OR cefazaflur[tiab] OR cefazedone[tiab] OR cefazolin[tiab] OR cefbuperazone[tiab] OR cefcanel[tiab]OR cefcapene[tiab]
OR cefclidin[tiab] OR cefdaloxime[tiab] OR cefdinir[tiab] OR cefditoren[tiab] OR cefedrolor[tiab] OR cefempidone[tiab] OR ce-
fepime[tiab] OR cefetamet[tiab] OR cefetecol[tiab] OR cefetrizole[tiab] OR cefiderocol[tiab] OR cefilavancin[tiab] OR cefivitril[tiab]
OR cefixime[tiab] OR cefluprenam[tiab] OR cefmatilen[tiab] OR cefmenoxime[tiab] OR cefmepidium[tiab] OR cefmetazole[tiab]
OR cefminox[tiab] OR cefodizime[tiab] OR cefonicid[tiab] OR cefoperazone[tiab] OR ceforanide[tiab] OR cefoselis[tiab] OR cefo-
taxime[tiab] OR cefotetan[tiab] OR cefotiam[tiab] OR cefovecin[tiab] OR cefoxazole[tiab] OR cefoxitin[tiab] OR cefozopran[tiab]
OR cefpimizole[tiab] OR cefpiramide[tiab] OR cefpirome[tiab] OR cefpodoxime[tiab] OR cefprozil[tiab] OR cefquinome[tiab]
OR cefradine[tiab] OR cefrotil[tiab] OR cefroxadine[tiab] OR cefsulodin[tiab] OR cefsumide[tiab] OR ceftaroline[tiab] OR cef-
tazidime[tiab] OR cefteram[tiab] OR ceftezole[tiab] OR ceftibuten[tiab] OR ceftiofur[tiab] OR ceftiolene[tiab] OR ceftioxide[tiab]
OR ceftizoxime[tiab] OR ceftobiprole[tiab] OR ceftolozane[tiab] OR ceftriaxone[tiab] OR cefuracetime[tiab] OR cefuroxime[tiab]
OR cefuzonam[tiab] OR cephacetrile[tiab] OR cephadroxil[tiab] OR cephaclor[tiab] OR cephadroxil[tiab] OR cephalexin[tiab] OR
cephaloglycin[tiab] OR cephalonium[tiab] OR cephaloram[tiab] OR cephaloridine[tiab] OR cephalotin[tiab] OR cephamandole[tiab]
OR cephaparole[tiab] OR cephapirin[tiab] OR cephatriaxone[tiab] OR cephatrizine[tiab] OR cephazaflur[tiab] OR cephazedone[tiab]
OR cephazolin[tiab] OR cephbuperazone[tiab] OR cephcanel[tiab] OR cephcapene[tiab] OR cephclidin[tiab] OR cephdaloxime[tiab]
OR cephdinir[tiab] OR cephditoren[tiab] OR cephedrolor[tiab] OR cephempidone[tiab] OR cephepime[tiab] OR cephetamet[tiab]
OR cephetecol[tiab] OR cephetrizole[tiab] OR cephiderocol[tiab] OR cephilavancin[tiab] OR cephivitril[tiab] OR cephixime[tiab]
OR cephluprenam[tiab] OR cephmatilen[tiab] OR cephmenoxime[tiab] OR cephmepidium[tiab] OR cephmetazole[tiab] OR ceph-
minox[tiab] OR cephodizime[tiab] OR cephonicid[tiab] OR cephoperazone[tiab] OR cephoranide[tiab] OR cephoselis[tiab] OR
cephotaxime[tiab] OR cephotetan[tiab] OR cephotiam[tiab] OR cephovecin[tiab] OR cephoxazole[tiab] OR cephoxitin[tiab] OR
cephozopran[tiab] OR cephpimizole[tiab] OR cephpiramide[tiab] OR cephpirome[tiab] OR cephpodoxime[tiab] OR cephprozil[tiab]
OR cephquinome[tiab] OR cephradine[tiab] OR cephrotil[tiab] OR cephroxadine[tiab] OR cephsulodin[tiab] OR cephsumide[tiab]
OR cephtaroline[tiab]OR cephtazidime[tiab] OR cephteram[tiab]OR cephtezole[tiab]OR cephtibuten[tiab] OR cephtiofur[tiab] OR
cephtiolene[tiab] OR cephtioxide[tiab] OR cephtizoxime[tiab] OR cephtobiprole[tiab] OR cephtolozane[tiab] OR cephtriaxone[tiab]
OR cephuracetime[tiab] OR cephuroxime[tiab] OR cephuzonam[tiab])
AND
(“Placebos”[Mesh] OR Placebos[tiab] OR Placebo[tiab] OR “Sham treatment”[tiab])
AND
((randomized controlled trial[Publication Type]OR controlled clinical trial[Publication Type]OR randomized[Title/Abstract] OR ran-
domised[Title/Abstract] OR placebo[Title/Abstract] OR “drug therapy”[MeSH Terms] OR randomly[Title/Abstract] OR trial[Title/
Abstract] OR groups[Title/Abstract]) NOT (Animals[Mesh] not (Animals[Mesh] and Humans[Mesh]/)))
Appendix 2. List of all cephalosporin antibiotics (International Nonproprietary Names)
cefacetrile
cefaclor
cefadroxil
cefalexin
cefaloglycin
cefalonium
cefaloram
cefaloridine
cefalotin
cefamandole
cefaparole
cefapirin
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cefatrizine
cefazaflur
cefazedone
cefazolin
cefbuperazone
cefcanel
cefcanel daloxate
cefcapene
cefclidin
cefdaloxime
cefdinir
cefditoren
cefedrolor
cefempidone
cefepime
cefetamet
cefetecol
cefetrizole
cefiderocol
cefilavancin
cefivitril
cefixime
cefluprenam
cefmatilen
cefmenoxime
cefmepidium chloride
cefmetazole
cefminox
cefodizime
cefonicid
cefoperazone
ceforanide
cefoselis
cefotaxime
cefotetan
cefotiam
cefovecin
cefoxazole
cefoxitin
cefozopran
cefpimizole
cefpiramide
cefpirome
cefpodoxime
cefprozil
cefquinome
cefradine
cefrotil
cefroxadine
cefsulodin
cefsumide
ceftaroline fosamil
ceftazidime
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cefteram
ceftezole
ceftibuten
ceftiofur
ceftiolene
ceftioxide
ceftizoxime
ceftizoxime alapivoxil
ceftobiprole
ceftobiprole medocaril
ceftolozane
ceftriaxone
cefuracetime
cefuroxime
cefuzonam
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